Follistatin-344

Follistatin 344 is described as a natural protein found in many living organisms’ tissues. It binds to proteins like activin and myostatin, which is discussed in the context of promoting muscle growth and helping regulate cell proliferation. It’s also noted for roles in muscle development, inflammation, embryo growth, and fertility.

Deeper Research Notes (Summary):
• Described as binding activin and myostatin; blocking myostatin is discussed for supporting muscle growth, while inhibiting activin is discussed for balancing growth and tissue repair.
• Described as improving insulin-related function by encouraging beta-islet cell growth in the pancreas, which may help regulate blood sugar levels and enhance overall insulin response.
• Described as having complex effects in cancer contexts: encouraging cell growth while also potentially helping prevent cancer from spreading to other body parts (reduced invasiveness is discussed as potentially improving survival odds).
• Compared to Follistatin 315, Follistatin 344 is described as a longer variant with weaker binding to myostatin(potentially less potent muscle regeneration), but with broader benefits due to additional binding regions—discussed across tissues (e.g., reproductive hormone regulation, cancer contexts, and organ-protection support).

Caution & Contraindications:
Caution:
• Individuals with diabetes may have a greater risk of developing side effects associated with follistatin
• High levels of follistatin have been associated with heart failure, mortality, and kidney disease
Contraindications: None listed at the moment due to limited research.

Reconstitution Options (Vial Format):
• 1 mg

Reconstitution (General Handling):
• Use sterile technique and sanitize the vial stopper before access.
• Add bacteriostatic water slowly along the vial wall to minimize foaming.
• Gently swirl/roll until fully dissolved (avoid vigorous shaking).
• Store according to the product label/spec sheet and protect from light as applicable.

Sequence (344 aa): MVRARHQPGG LCLLLLLLCQ FMEDRSAQAG NCWLRQAKNG RCQVLYKTEL SKEECCSTGR LSTSWTEEDV NDNTLFKWMIF NGGAPNCIPCK ETCENVDCGP GKKCRMNKKN KPRCVCAPDCS NITWKG PVCGLDGKTYR NECALLKARCK EQPELEVQYQG RCKKTCRDVFC PGSSTCVVDQT NNAYCVTCNRI CPEPASS EQYLCGNDGVT YSSACHLRKAT CLLGRSIGLAY EGKCIKAKSC EDIQCTGGKKC LWDFK VGRGRCSLCDE LCPDSKSDEP VCASDNATYAS ECAMKEAACSS GVLLEVKHS GSCNSISEDTE EEEDEDQDYS FPISSILEW

Molecular Weight: ~37.8 kDa

PubChem CID: 178101631

Synonyms: Activin-binding protein, FSH-suppressing protein, FST-344

Eight-week murine studies reported ~10% gains in lean muscle mass following Follistatin-344 injections without exercise conditioning. Duchenne muscular dystrophy models displayed improved strength, lower inflammation, and reduced scar tissue in a dose-dependent fashion. Gene-delivery approaches delivered multi-year hypertrophy, suggesting Follistatin-344 could supplement current strategies for muscle-wasting disorders.

Mechanistically, Follistatin-344 boosts insulin/IGF-1 pathway signaling and stimulates pancreatic insulin output, underscoring cross-talk between endocrine and musculoskeletal systems.

Clinical profiling of breast tumors shows that low FST expression correlates with aggressive disease, while overexpression can enlarge tumors yet reduce invasion and metastasis. In HER2-positive mouse models, exogenous follistatin prevented activin-driven migration and eliminated lung metastases despite unchanged primary tumor size.

Hepatic studies indicate follistatin-mediated activin blockade is necessary for hepatocyte proliferation, highlighting the nuanced balance between local tissue growth and systemic safety.

Follistatin-344 is being evaluated to counter excessive BMP signaling in Barrett’s esophagus, a precancerous state triggered by chronic reflux. Dermatologic trials combining follistatin with Wnt agonists reported ~20% increases in hair density and 13% increases in shaft thickness one year after a single intradermal injection.

In diabetic mouse models, sustained follistatin expression expanded beta-islet cell mass, normalized fasting glucose, and doubled lifespan by reducing complications—a compelling avenue for metabolic research.

Follistatin-344 neutralizes key TGF-β ligands to promote muscle anabolism, temper fibrosis, regulate endocrine function, and influence oncologic behavior. Murine data show low oral and robust subcutaneous bioavailability with moderate side effects. Animal dosing does not extrapolate to humans; the peptide is restricted to licensed researchers conducting in-vitro or controlled laboratory investigations.

PubMed

Article Author :

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from https://case.edu/medicine/Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Case Western Reserve University School of Medicine

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The product information featured on this website pertains exclusively to in-vitro studies. In-vitro studies, also known as ‘in glass’ studies, are conducted outside of living organisms. It’s important to emphasize that these products do not constitute medicines or drugs and have not received FDA approval for the prevention, treatment, or cure of any medical conditions, ailments, or diseases. It is crucial to note that the introduction of these products into the bodies of humans or animals is strictly prohibited by law.